Optimizing CAR T-Cell Therapy in DLBCL With Community and Academic Perspectives - Episode 2
Bispecific Antibodies vs CAR T-Cell Therapy: Treatment Selection and Sequencing in Later-Line R/R DLBCL
Experts discuss how they sequence bispecifics and other available therapies in the third-line setting and beyond for patients who did not receive chimeric antigen receptor T-cell therapy (CAR T) in the second-line setting, and whether their approach changes for those who have or have not received prior auto-transplant.
Video content above is prompted by the following:
How are you sequencing other available therapies like bispecifics in the third-line setting and beyond for those who didn't get CAR T in the second-line setting? Does your thought process change for those who received prior auto-transplant or not?
Related Content:
